)
Peter Keller
CEO
BlueWhale Bio
Peter is the founding CEO of BlueWhale Bio and led the company from inception to its first clinical trial in less than 18 months. Earlier in his career, he helped secure more than $200 million in private funding, negotiated licensing deals with Abbott, Sanofi, and Spark Therapeutics, and contributed to Selecta Biosciences’ $70 million IPO. He also helped shape the early strategy of Inventiva Pharma, Monopteros Therapeutics, and Disarm Therapeutics, later acquired by Eli Lilly. Previously, he was Vice President at Solvay Pharmaceuticals and Abbott Laboratories, where he led the integration following Abbott’s $6.2 billion acquisition of Solvay. He began his career at McKinsey & Co. and Simon-Kucher.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}